Public opinion towards supervised injection facilities and heroin-assisted treatment in Ontario, Canada

International Journal of Drug Policy

Volumn 18, Issue 1, 2007, Pages 54-61

  Cruz, Michelle Firestone ^a   Patra, Jayadeep ^a,c   Fischer, Benedikt ^a,b   Rehm, Jürgen ^a,c,d   Kalousek, Kate ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF VICTORIA   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d Institut fur Sucht und Gesundheitsforschung Zurich   (Switzerland)

Author keywords

Canada; Government; Harm reduction; Heroin assisted treatment (HAT); Public opinion; Public policy; Supervised injection facility (SIF)

Indexed keywords

CANNABIS; COCAINE; DIAMORPHINE; ILLICIT DRUG;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CANADA; CONTROLLED STUDY; DATA ANALYSIS; DATA BASE; DRUG ABUSE; DRUG SELF ADMINISTRATION; DRUG USE; FEMALE; HEALTH CARE FACILITY; HUMAN; MALE; MENTAL HEALTH CENTER; NEEDLE; PRIORITY JOURNAL; PRISON; PUBLIC OPINION; RANDOM SAMPLE; STATISTICAL SIGNIFICANCE; STUDENT T TEST; SUPERVISED INJECTION FACILITY;

ADULT; AGED; AGED, 80 AND OVER; EDUCATIONAL STATUS; FEMALE; HARM REDUCTION; HEROIN DEPENDENCE; HUMANS; INTERVIEWS; MALE; MIDDLE AGED; ONTARIO; PUBLIC FACILITIES; PUBLIC OPINION; PUBLIC POLICY; SOCIOECONOMIC FACTORS; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 33846909559     PISSN: 09553959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugpo.2006.12.001     Document Type: Article

References (53)

1. Bammer G., Dobler-Mikola A., Fleming P., Strang J., and Uchtenhagen A. The heroin prescribing debate: Integrating science and politics. Science 284 (1999) 1277-1278
2. Bammer G., van den Brink W., Gschwend P., Hendriks V., and Rehm J. What can the Swiss and Dutch trials tell us about the potential risks associated with heroin prescribing?. Drug and Alcohol Review 22 (2003) 363-371
3. Broadhead R.S., Kerr T.H., Grund J.-P., and Altice F.L. Safer injection facilities in North America: Their place in public policy and health initiatives. Journal of Drug Issues 32 (2002) 329-355
4. Cain, V. (2004). Report of the Task Force into Illicit Narcotic Overdose Deaths in British Columbia.
5. Centers for Disease Control (CDC). (2003). Behavioral Risk Factor Surveillance System: Summary Data Quality Report.
6. Charland L. Cynthia's dilema: Consenting to heroin prescription. American Journal of Bioethics 2 (2002) 37-47
7. Cronbach L. Coefficient alpha and the internal structure of tests. Psychometrika 16 (1951) 297-334
8. Darke S., and Ross J. Fatal heroin overdoses resulting from non-injecting routes of administration, NSW, Australia, 1992-1996. Addiction 95 (2000) 569-573
9. Fischer B. Prohibition, public health and a window of opportunity: An analysis of Canadian drug policy, 1985-1997. Policy Studies 20 (1999) 197-210
10. Fischer B., Brissette S., Brochu S., Bruneau J., el-Guebaly N., Noel L., et al. Prevalence and determinants of overdose incidents among illicit opioid users in five cities across Canada. Canadian Medical Association Journal 171 (2004) 235-239
11. Fischer B., Haydon E., Rehm J., Krajden M., and Reimer J. Injection drug use and the hepatitis C virus: Considerations for a targeted treatment approach-The case study of Canada. Journal of Urban Health 81 (2004) 428-447
12. Fischer B., Popova L., Rehm J., and Ivsins A. Drug use related overdose mortality in British Columbia and Ontario, 1992-2002. Canadian Journal of Public Health 97 (2006) 384-387
13. Fischer B., and Rehm J. The case for a heroin substitution treatment trial in Canada. Canadian Journal of Public Health 88 (1997) 367-370
14. Fischer B., Rehm J., Kim G., and Robins A. Safer Injection Facilities (SIFs) for Injection Drug Users (IDUs) in Canada: A review and call for an evidence-focused pilot trial. Canadian Journal of Public Health 93 (2002) 336-338
15. Fischer B., Rehm J., Kirst M., Casas M., Hall W., Krausz M., et al. Heroin-assisted treatment as a response to the public health problem of opiate dependence. European Journal of Public Health 12 (2002) 228-234
16. Freeman K., Jones C., Weatherburn D., Rutter S., Spooner C., and Donnelly N. The impact of the Sydney Medically Supervised Injection Centre (MSIC) on crime. Drug Alcohol Review 24 (2005) 173-184
17. Frei A. Economic evaluation of the Swiss project on medically prescribed heroin substitution treatment. Psychiatrische Praxis 28 (2001) S41-S44
18. Giesbrecht N., and Ialomiteanu A. Trends in public opinion on alcohol policy measures: Ontario 1989-1998. Journal of Studies on Alcohol 62 (2001) 142-149
19. Hankins C. Syringe exchange in Canada: Good but not enough to stem the HIV tide. Substance Use & Misuse 33 (1998) 1129-1145
20. Health Canada. (2006). No new injection sites for addicts until questions answered says Minister Clement. Health Canada [On-line]. Available: http://www.hc-sc.gc.ca/ahc-asc/media/nr-cp/2006/2006_85_e.html.
21. Hedrich D. European report on drug consumption rooms (2004), European Monitoring Centre on Drugs and Drug Addiction (EMCDDA), Lisbon
22. Hurley S., Jolley D., and Kaldor J. Effectiveness of needle-exchange programmes for prevention of HIV infection. The Lancet 349 (1997) 1797-1800
23. Ialomiteanu A., and Adlaf E. CAMH Monitor: Technical Guide 2003 (2004). www.camh.net/research/population_life_course.html
24. Independent Working Group. (2006). The Report of the Independent Working Group on Drug Consumption Rooms. United Kingdom: Joseph Rowntree Foundation.
25. International Symposium for Heroin-Assisted Treatment (ISHAT). (2006). Heroin-assisted treatment: An innovative element of the drug support system, Cologne, Germany, March 23-25.
26. Kahan M., Srivastava A., and Shen K. Why we object to NAOMI. Heroin maintenance in Canada. Canadian Family Physician 52 (2006) 709-711
27. Kerr T., and Palepu A. Safe injection facilities in Canada: Is it time?. Canadian Medical Association Journal 165 (2001) 436-437
28. Kerr T., Stoltz J., Tyndall M., Li K., Zhang R., Montaner J., et al. Impact of a medically supervised injection facility on community drug use patterns: A before and after study. British Medical Journal 332 (2006) 220-222
29. Kimber J., Dolan K., and Wodak A. Survey of drug consumption rooms: Service delivery and perceived public health and amenity impact. Drug and Alcohol Review 24 (2005) 21-24
30. MSIC Evaluation Committee. (2003). Evaluation of the Medically-Supervised Injecting Centre (MSIC). Sydney: MSIC Evaluation Committee.
31. Nadelmann E., McNeely J., and Drucker E. Harm reduction drug control strategies: A global perspective. In: Lowinson J., Ruiz P., and Millman R. (Eds). Substance abuse: A comprehensive textbook (1997), Williams and Wilkins, Baltimore 22-39
32. Orner M., Meehan T., Brooks D., Mucci L., and McGuire J. Support for condom availability and needle exchange programs among Massachusetts adults, 1997. AIDS Education and Prevention 13 (2001) 365-376
33. Public Health Agency of Canada (PHAC). (2003). Estimates of HIV Prevalence and Incidence in Canada, 2002 (Rep. No. 29-23).
34. Poschadel, S., Höger, R., Schintzler, J., & Schreckenberger, J. (2002). Evaluation der Arbeit Drogenkonsumräume in der Bundesrepublik Deutschland: Endbericht im Auftrag des Bundesministeriums für Gesundheit. In Das Bundesministerium für Gesundheit und Soziale Sicherung (Schriftenreihe Bd 149). Baden-Baden: Nomos-Verlags-Gesellschaft.
35. Rehm J., Gschwend P., Steffen T., Gutzwiller F., Dobler-Mikola A., and Uchtenhagen A. Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: A follow-up study. The Lancet 358 (2001) 1417-1420
36. Rihs-Middel M. Die Heroinvergabe im Spannungsfeld von Forschung und Praxis. In: Westermann B., Bellman G., and Jellinek C. (Eds). Heroinverschreibung: Wirkungen und Nebenwirkungen (1999), Deutscher Studien Verlag, Köln 77-113
37. Salmon, A., Thein, H.-H., Kimber, J., Kaldor, J., & Maher, L. (2007). Five years on: What are the community perceptions of drug-related public amenity following the establishment of the Sydney Medically Supervised Injecting Centre? International Journal of Drug Policy, 18 (1), doi:10.1016/j.drugpo.2006.11.010.
38. Schechter M.T. NAOMI-her time has come. North American Opiate Medication Initiative. Journal of Urban Health 79 (2002) 164-165
39. Solomon R., Single E., and Erickson P. Legal considerations in Canadian cannabis policy. Canadian Public Policy 9 (1983) 419-433
40. Stimson G., and Metrebian N. Prescribing heroin: What is the evidence? (2003), Joseph Rowntree Foundation, York, England
41. Strathdee S., and Vlahov D. The effectiveness of needle exchange programs: A review of the science and policy. AID Science 1 (2001)
42. Tardiff K., Marzuk P., Leon A., Portera L., Hartwell N., Hirsch C., et al. Accidental fatal drug overdoses in New York City: 1990-1992. American Journal of Drug and Alcohol Abuse 22 (1996) 135-146
43. Thein H., Kimber J., Maher L., MacDonald M., and Kaldor J. Public opinion towards supervised injecting centres and the Sydney Medically Supervised Injecting Centre. International Journal of Drug Policy 16 (2005) 275-280
44. Trewin D., and Lee G. International comparisons of telephone coverage. In: Groves R., Biemer Q., Lyberg L., Massey J.T., Nicholls W., and Waksberg J. (Eds). Telephone survey methodology (1988), John Wiley & Sons, New York 9-24
45. Uchtenhagen A. Drug law and policy reform in Switzerland: Briefing paper for RSA commission (2006), Research Institute for Public Health and Addiction, Zurich
46. Vernick J., Burris S., and Strathdee S. Public opinion about syringe exchange programmes in the USA: An analysis of national surveys. International Journal of Drug Policy 14 (2003) 431-435
47. Wodak A. Prescribing heroin: Nothing to fear but fear itself?. Medical Journal of Australia 168 (1998) 590-591
48. Wood E., Tyndall M., Stoltz J., Small W., Lloyd-Smith E., Zhang C., et al. Factors associated with syringe sharing among users of a medically supervised safer injecting facility. American Journal of Medical Sciences 1 (2005) 50-54
49. Wood E., Tyndall M., Lai C., Montaner J., and Kerr T. Impact of a medically supervised safer injecting facility on drug dealing and other drug-related crime. Substance Abuse Treatment, Prevention and Policy 1 (2006) 13
50. Wood E., Tyndall M., Qui Z., Zhang R., and Montaner J. Service uptake and characteristics of injection drug users utilizing North America's first medically supervised safer injecting facility. American Journal of Public Health 96 (2006) 770-773
51. Woods A. Ottawa ignores support for injection sites-Harper government froze new sites even though own poll showed backing for them. The Vancouver Sun November (2006)
52. Zou S., Forrester L., and Giulivi A. Hepatitis C update. Canadian Journal of Public Health 94 (2003) 127-129
53. Zurhold H., Degkwitz P., Verthein U., and Haasen C. Drug consumption rooms in Hamburg, Germany: Evaluation of the effects on harm reduction and the reduction of public nuisance. The Journal of Drug Issues 33 (2003) 663-688